Sona Nanotech Inc (SONA) AI Stock Analysis

• Market Cap: C$29.79M
• Dividend Yield: N/A
• Average Volume (3M): 26.18K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.57
• Revenue Growth: N/A
• EPS Growth: 5.23%
• Country: CA
• Employees: 8
• Sector: Healthcare
• Sector Strength: 64
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.03
• Shares Outstanding: 108,340,440
• 10 Day Avg. Volume: 11,962
• 30 Day Avg. Volume: 26,184
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -8.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Sona Nanotech Inc. faces substantial financial challenges with zero revenue and persistent losses, significantly affecting its stock score. While technical indicators and valuation metrics show mixed signals, recent promising developments in cancer therapy provide some optimism for future prospects. However, the company's reliance on external financing and high liabilities remain key risks.

Sona Nanotech Inc Business Overview & Revenue Model

Company Description

Sona Nanotech Inc (SONA) is a nanotechnology company specializing in the development and commercialization of innovative nanomaterials for diagnostic and medical applications. The company operates primarily in the biotechnology and life sciences sectors, offering products such as gold nanorods for use in lateral flow assays and other diagnostic tests. Sona Nanotech is committed to advancing healthcare by providing high-performance, cost-effective solutions that enhance the accuracy and efficiency of diagnostic testing.

How the Company Makes Money

Sona Nanotech Inc generates revenue primarily through the sale of its proprietary nanomaterials, including gold nanorods, which are utilized in the production of diagnostic assays and other medical technologies. The company monetizes its technology by supplying these nanomaterials to diagnostic test manufacturers, research institutions, and healthcare companies. Additionally, Sona Nanotech may engage in licensing agreements and partnerships with other organizations to expand the application of its technologies and reach new markets. While direct sales of its nanomaterials form the core revenue stream, strategic collaborations and research grants may also contribute to the company's earnings.

Sona Nanotech Inc Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-553.98K	-456.76K	-60.32K	-65.59K	-66.37K	-51.10K
	EBIT
-2.24M	-2.61M	-2.68M	-10.35M	-6.25M	-1.46M
	EBITDA
-1.92M	-2.02M	-2.34M	-10.38M	-6.24M	-1.41M
	Net Income Common Stockholders
-2.70M	-2.50M	-2.45M	-10.77M	-6.06M	-2.94M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.86M	115.38K	164.42K	1.20M	110.78K	585.16K
	Total Assets
3.75M	2.75M	520.77K	1.52M	724.63K	859.21K
	Total Debt
394.67K	527.68K	608.47K	1.34M	1.49M	1.16M
	Net Debt
-1.46M	418.30K	453.05K	152.81K	1.39M	582.82K
	Total Liabilities
1.24M	1.59M	1.03M	2.75M	4.16M	1.88M
	Stockholders Equity
2.51M	1.16M	-507.86K	-1.22M	-3.44M	-1.02M
Cash Flow		Free Cash Flow
-1.96M	-1.26M	-1.81M	-3.81M	-4.75M	-1.52M
	Operating Cash Flow
-1.96M	-1.26M	-1.81M	-3.81M	-4.05M	-1.36M
	Investing Cash Flow
0.00	14.64K	0.00	0.00	-694.01K	-158.73K
	Financing Cash Flow
3.70M	1.20M	―	4.89M	4.27M	298.63K

Sona Nanotech Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.28
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:SONA, the sentiment is Positive. The current price of 0.28 is above the 20-day moving average (MA) of 0.28, below the 50-day MA of 0.30, and above the 200-day MA of 0.28, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.69 is Neutral, neither overbought nor oversold. The STOCH value of 48.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:SONA.

Sona Nanotech Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MBX	66 Neutral	C$49.36M	24.65	6.85%	―	2.72%	-47.79%
Sector *	51 Neutral	$5.20B	3.18	-40.80%	2.96%	17.66%	1.94%
NANO	45 Neutral	C$73.55M	―	-84.80%	―	―	13.34%
SONA	42 Neutral	C$29.79M	―	-196.80%	―	―	5.23%

Sona Nanotech Inc Corporate Events

Sona Nanotech’s Cancer Therapy Shows Promising Preclinical Results

Sona Nanotech Inc. has released new preclinical data demonstrating the efficacy of its Targeted Hyperthermia Therapy (THT) in inhibiting tumor growth in an immunotherapy-resistant colorectal cancer model. The study showed that THT, when used in conjunction with a PD-1 inhibitor, resulted in a significant arrest of tumor growth in all test subjects. This promising result underscores the potential of THT to enhance the effectiveness of existing immunotherapies, positioning Sona as a significant player in cancer treatment innovation. The company is also engaging Proactive Investors North America Inc. to boost its global profile and public awareness.

Sona Nanotech to Present Innovative Cancer Therapy at Canadian Melanoma Conference

Sona Nanotech Inc. announced that its study on targeted intra-tumoral hyperthermia using biocompatible gold nanorods will be presented at the upcoming Canadian Melanoma Conference. This presentation highlights Sona’s innovative approach to cancer treatment, potentially impacting the industry by providing a safe, effective, and minimally invasive therapy option, which may serve as a valuable adjunct to existing treatments.